Daniel is an Associate Director in Osborne Clarke's dispute resolution team, with expertise in international arbitration.

He has acted as counsel in both international commercial and investment treaty arbitrations, representing and advising clients in a range of sectors including energy, life sciences and telecommunications. Daniel has conducted both ad hoc and institutional arbitrations, including under the LCIA, ICC, SCC, ICSID and UNCITRAL rules.

Daniel also advises clients on high-value litigation at all levels of the English court system.

Before joining Osborne Clarke in May 2019, Daniel practised at Latham & Watkins for seven years, where he was a member of the international arbitration group.

Helping you succeed in tomorrow's world

Daniel is a leader of the London Branch of the Young Members Group of the Chartered Institute of Arbitrators.

Daniel is committed to social mobility, having presented at schools in East London on legal careers and mentored their university applicants, and is a leader of the firm's Social Diversity Initiative.

Work

BIT arbitration

Representing an investor in an SCC arbitration relating to breaches of a bilateral investment treaty by an Eastern European state.

ECT arbitration

Representing the respondent state in a multibillion US dollar SCC arbitration relating to breaches of the Energy Charter Treaty.

ECT arbitration:

Advising an investor in the Spanish solar sector in relation to its claim under the Energy Charter Treaty.

ECT and BIT arbitration:

Representing an energy company in an ICSID arbitration involving issues under the Energy Charter Treaty and a bilateral investment treaty relating to energy concessions.

BIT arbitration

Representing a construction company in an ICSID arbitration involving issues under a bilateral investment treaty relating to a construction project.

Commercial arbitration

Representing a multinational oil company in an UNCITRAL arbitration relating to the construction of pipelines in Nigeria administered by the PCA.

Commercial arbitration

Representing a pharmaceutical company in an ICC arbitration relating to a half a billion US dollar claim over a joint venture.

Insights